Skip to content

Efficacy of IgM Rich Immunoglobulin With Antibiotics for Bacterial Sepsis in Very Low Birth Weight Preterm Neonates

A Prospective Study to Analyze the Efficacy of IgM Rich Immunoglobulin as an Adjunct to Antibiotics in the Treatment of Bacterial Sepsis in Very Low Birth Weight Preterm Neonates

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03403530
Acronym
IgMNS
Enrollment
60
Registered
2018-01-18
Start date
2018-01-30
Completion date
2018-09-30
Last updated
2020-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal SEPSIS, Very Low Birth Weight Baby

Keywords

IgM, Immunoglobulin, Neonatal sepsis, very low birth weight preterm

Brief summary

Study comprises of giving IVIG to half of the septic VLBW preterm neonates along with ongoing antibiotics and placebo to the other half. The immunoglobulin will be given for 3 days and neonates will be monitored for the results. The data will be analysed on the basis of blood culture results and outcome of the patients.

Interventions

DRUGIgM rich Immunoglobin

the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg

Sponsors

Sir Takhtasinhji General Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
1 Days to 30 Days
Healthy volunteers
No

Inclusion criteria

* Preterm * Very low birth weight baby: birth weight 1-1.5 kg * Both inside and outside delivered babies * Gender: males and females * Probable severe sepsis (septic score)

Exclusion criteria

* Extremely low birth weight babies: \< 1 kg * Babies \>1.5 kg birth weight * Babies born with congenital malformations * Full term babies * IUGR babies * Child with no signs of sepsis * HBsAg Positive * HIV Positive

Design outcomes

Primary

MeasureTime frameDescription
Discharge rates6 monthspatients who received IgM rich Immunoglobin along with antibiotics have better outcome as compared to the patients who receive only antibiotics.

Secondary

MeasureTime frameDescription
Duration of hospital stay6 monthspatients who received IgM rich Immunoglobin along with antibiotics have better outcome as compared to the patients who receive only antibiotics.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026